Pre-Treatment Lactate Dehydrogenase to Albumin Ratio (LAR) Predicts Distant Metastasis and Poor Survival in Nasopharyngeal Carcinoma

Shu-lan Chen, Jun Li, Jin-gao Li, Xiao-ting Pan, Hong-wen Wu, Fei Xu

PDF(2149 KB)
JBRHA
Journal of Biological Regulators and Homeostatic Agents ›› 2022, Vol. 36 ›› Issue (6) : 2139-2147. DOI: 10.23812/j.biol.regul.homeost.agents.20223606.221
Article

Pre-Treatment Lactate Dehydrogenase to Albumin Ratio (LAR) Predicts Distant Metastasis and Poor Survival in Nasopharyngeal Carcinoma

    {{javascript:window.custom_author_en_index=0;}}
  • {{article.zuoZhe_EN}}
Author information +
History +

Highlight

{{article.keyPoints_en}}

Abstract

{{article.zhaiyao_en}}

Key words

Cite this article

EndNote

Ris (Procite)

Bibtex

Download Citations
{{article.zuoZheEn_L}}. {{article.title_en}}. {{journal.qiKanMingCheng_EN}}. 2022, 36(6): 2139-2147 https://doi.org/10.23812/j.biol.regul.homeost.agents.20223606.221

References

Publishing order | Descend order by publishing year | Descend order by cited within

References

{{article.reference}}

Funding

RIGHTS & PERMISSIONS

{{article.copyrightStatement_en}}
{{article.copyrightLicense_en}}
Article Options
  • PDF (31 views)
  • Full Text ( views)

Accesses

Citation

Detail
Sections
Recommended

Journal Info

About JBRHA
Indexing & Archiving
Editorial Board
Open Access
Copyright & License

For Authors

Submit
Instructions for Authors
Editorial Process
Article Processing Charge

For Reviewers

Online Review
Guidelines for Reviewers
Peer Review Process

Articles

Current Issue
Archives
Follow Us on
Copyright © 2023 Biolife Sas.
  • Disclaimer
    The statements, opinions and data contained in Journal of Biological Regulators and Homeostatic Agents are solely those of the individual authors and contributors and not of the journal and the editor(s). Journal of Biological Regulators and Homeostatic Agents stays neutral with regard to jurisdictional claims in published maps and insitutional affiliations.
    • 　　Terms & Conditions　　 Terms & Use　　　 Privacy Policy　

    /

    〈 〉